Formulary guidance and transparency from P&T to point of care

Trends that Matter for Highly Managed Classes

Posted by Matt Breese on Nov 3, 2016

Find me on:

In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's top pharma topic is highly managed classes.

Highly managed products include specialty drugs, used to treat complex illnesses such as cancer, multiple sclerosis, HIV, rheumatoid arthritis, and hepatitis C. These treatments require ongoing patient education and monitoring.

According to HIT Consultant, In 2014, “70% of all medication approvals by the Food and Drug Administration (FDA) were for specialty drugs.”

Specialty drugs have been in the spotlight in recent years as healthcare professionals discuss who will be responsible for paying for these treatments in upcoming years, HIT predicts, “Consumers may pay for a smaller portion of specialty drug costs than for traditional drugs.” Meanwhile, public payers will continue to experience increased costs.

The infographics below, created by HIT Consultant, capture trends in specialty pharmaceuticals from 2011-2020.

Specialty Drugs 1.png

Specialty Drugs 2.png

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Industry Trends, Payer